Clinical Trial Detail

NCT ID NCT02077933
Title Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors Novartis Pharmaceuticals

pancreatic endocrine carcinoma

kidney cancer

Advanced Solid Tumor

breast cancer


Alpelisib + Everolimus

Alpelisib + Everolimus + Exemestane

Age Groups: senior adult

No variant requirements are available.